Breast Cancer Clinical Roundup
News Articles
(Pfizer) Oct 9, 2020 - The German Breast Group and Pfizer Inc. today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have...
(FDA in Brief) Oct 7, 2020 - “Today, the U.S. Food and Drug Administration issued draft guidance encouraging the inclusion of premenopausal women in breast cancer clinical trials that investigate the efficacy of hormonal drug and biological products.”
"When finalized, the guidance will provide recommendations for industry to...
(EBCC 12) Oct 3, 2020 - Final results of nine-year survival outcomes from NeoALTTO BIG-06 trial for patients with HER2-positive breast cancer.
(Markets Insider) Oct 2, 2020 - Study in over 500 patients with node-negative or node-positive disease highlights impact of the test on treatment decisions, reducing potential over- and under-treatment and leading to a 23.5% net reduction in chemotherapy recommendations.
Publications
(Breast cancer research and treatment) - 2020-10-09
(Breast cancer research and treatment) - 2020-10-09
(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-10-08
(JCO oncology practice) - 2020-10-07
Clinical Briefs
At ESMO Virtual Congress 2020, the results from two randomized phase 3 trials monarchE and ASCENT showed that success is possible for breast cancer subtypes that have long eluded treatment. However, the results of IMpassion131, IMpassion130, and IMpassion031 for atezolizumab were a mixed bag.
Follow @OBRTweets